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S_ry A major problem in cytostatic treatment of many tumours is the deveklopent of multidrug
resistance (MDR4). This is most often accompanied by the ovrexpon of a membrane transport protein,
P-glycoprotein, and its encoding mRNA. In order to reverse the resistant phenotype in cell cultures, we
constructed a specific hammerhead ribozyme possessing catalytic activity that cleaves the 3'-end of the GUC
sequence in codon 880 of the mdrl mRNA. We demonstrated that the constructed ribozyme is able to cleave a
reduced substrate mdrl mRNA at the GUC position under physiolgical conditions in a cell-free system. A
DNA sequence encoding the ribozyme gene was then incorporated into a mammahan expression vector
(pHPAPr-l neo) and transfected into the human pancreatic carcinoma cell line EPP85-181RDB, which is
resistant to daunorubicin and expresses the MDR phenotype. The expressed ribozyme decreased the level of
mdrl mRNA expression, inhibited the formation of P-glycoprotein and reduced the cell's resistance to
daunorubicin dramatically; this means that the resistant cells were 1,600-fold more resistant than the parental
cell line (EPP85-181P), whereas those cell clones that showed ribozyme expression were only 5.3-fold more
resistant than the parental cell line.
Chemotherapy has proved to be an effective strategy against
malignant tumours. However, during therapy many tumours
become resistant not only to the specific cytostatic drug with
which they are being treated and to which they were initially
sensitive, but also to many other compounds (cross-resis-
tance). This multidrug resistance is often mediated by the
enhanced expression of the mdrl gene (Gros et al., 1986;
Ueda et al., 1987). The product of the murl gene is a
glycoprotein (P-Gp) of 170 kDa molecular weight which is
found concentrated in the plasma membrane (Juliano &
Ling, 1976; Kartner et al., 1983, 1985). The overexpression of
P-Gp is accompanied by the enhanced synthesis of the 4.5 kb
mdrl mRNA (Roninson et al., 1986). P-Gp has a total length
of 1,280 amino acids, with two ATP binding sites. Further-
more, it has drug-binding properties (Cornwell et al., 1987)
and may function as an energy-dependent efflux pump (Pas-
tan & Gottesman, 1987). This is a reason why resistant
tumour cells show reduced drug accumulation, thus allowing
their survival at otherwise toxic drug concentrations
(Endicott & Ling, 1989).
Ribozymes have nucleolytic activity and are able to cleave
specific RNA sequences (Cech & Bass, 1986). Hammerhead
ribozymes are able to cleave the 3'-end of the triplet GUX
(where X is C, A or U) in RNA molecules. The central core
of the hammerhead is responsible for the cleavage reaction,
whereas the flanking sequences mediate specific binding to
the target RNA (Uhlenbeck, 1987; Haseloff & Gerlach, 1988;
Cameron & Jennings, 1989). Since such ribozymes can be
targeted to specific RNA sequences, they have proved to be
useful tools for inhibiting undesired gene expression. In tissue
culture assays, specific hamrhead ribozymes were able to
cleave human immunodeficiency virus type 1 (Sarver et al.,
1990), c-fos (Funato et al., 1992) and H-ras (Kashani-Sabet
et al., 1992).
In this paper we describe the construction of a ham-
merhead ribozyme that was directed against mdrl mRNA.
Cleavage specificity ofthe ribozyme was confirmed by in vitro
analysis. Additionally, the ribozyme was introduced in a
daunorubicin-resistant pancreatic carcinoma cell line to
evaluate its influence on the mdrl gene-mediated resistance of
this cell line.
Materals an netds
Construction ofthe ribozyme
A GUC site in codon 880 of exon 21 of the mdrl mRNA
was selected as the cleavage site of the ribozyme. The
ribozyme is shown in Figure la. For the in vitro analysis, it
consisted of a 43-base-long RNA molecule with the two
flanking sequences providing specific binding to the mdrl
mRNA and to the central core responsible for the cleavage
reaction at the GUC site.
Synthesis ofthe ribozyme
A 60 bp DNA strand was synthesised on a DNA synthesiser
(Applied Biosystem) that contained a T7 RNA polymerase
promoter sequence and the DNA sequence of the ribozyme
gene (ribol, TAATACGACTCACTATAGTGCITGTCCA-
CTGATGAGTCCGTGAGGACGAAACAACATITT, pro-
moter sequence underlined). A second 19-mer complementary
to the 3'-sequence of the 60bp fragment was synthesised
(ribo2, AAAATGTTG mTTCGTCCTC). Using these two
primers, the 60bp double-strand DNA molecule was
amplified by polymerase chain reaction (PCR). The resulting
product was transcribed in vitro.
Synthesis ofthe target RNA
For the generation of target RNA, two DNA primers were
synthesised to amplify a 200bp sequence of an mdrl cDNA
clone (plasmid PI4/HaeILH, k-indly provided by T. Hoof,
Hannover, Germany). The primer in exon 21 (primer A,
GAAGAATTCGCAATTGTACCCATCATTGC) contained
an EcoRI site, whereas the primer in exon 22 (primer B,
GAAGGATCCCCTGCAAACTCTGAGCAT) contained a
BanHI cleavage site. The 200 bp DNA fragment was cleaved
with EcoRJ and BamHI and ligated into pBLUESCRIPT H
SK plasmid, directly behind the T7 promoter. This plasmid
(pSAB I) was transfected into Escherichia coli by electropora-
tion (Gene Zapper, IBI). Colonies were selected and screened
for the presence of the plasmid pSAB I using EcoRI and
BamHI digestion. Following digestion of the plasmid pSAB I
with BamHI, in vitro transcription by T7 RNA polymerase
yielded a 240 base target RNA mokcule.
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Frw 1 a, Secondary structure of the anti-mdr ribozyme annealed to a part of 240bp of the exon 21 of the mdrl mRNA. Arrow, position of cleavage. b, Autoradiograph of a 10% polyacrylamide gel showing the time course of the in vitro cleavage of a 240 bp mdrl mRNA by the ribozyme at 42'C generating 137 and 103 base fragments. Lane 1, substrate RNA without a nbozyme; lane 2, 0min; lane 3, 30s; lane 4, 1 min; lane 5, 2min; lane 6, 5min; lane 7, 15min; lane 8, 30min; lane 9, 60min; lane 10, ribozyme without substrate RNA. c, RT-PCR combined with a Southern analysis to determine ribozyme expression in different cell clones using the ribozyme probe. A-D, transformed cel clones that were resistant against G418; E, cel line containing only the vector (EPP85-181RDB/Vec); F, positive control; G, EPP85-181P-, H, EPP85-181RDB. d, Part of the expression vector pHAAPr-l neo/mdr-Rb and the oligonucleotides used for detection of the expressed ribozyme. Arrows, position of splice
junctions.
In vitro trancrtion andpurificatin ofthe ribozyme and
target RNA
This was performed as described by Krupp (1988). Transcrip-
tion was carried out at 37C for 2 h. Radioactive labelling
was achieved by incubation in the presence of [a-2PJUTP
(800 Ci mmol ', Amersham). Target RNA and ribozyme
molecules were separated by electrophoresis on a 8% poly-
acrylamide-7 M urea gel. After autoradiography, the corre-
sponding bands that contained the ribozyme and the target
RNA were eluted from the polyacrylamide gel. To determine
the concentrations of purified RNAs, radioactivity was
measured in a scintillation counter.
In vitro cleavage reaction
The in vitro cleavage reaction was carried out in a final
volume of 10 lL. The incubation buffer contained 40 mm
Tris-HCI (pH 8.0) and 2 mM spermidine. In order to estab-
lish optimal in vitro cleavage conditions, the reactions were
defined for magnesium chloride (from 0 mM to 20mM),
temperature (between 22 C and 60C) and pH (between pH 5
and pH 9). Approximately 0.8 pmol of the ribozyme and
0.2 pmol of the target were used, resulting in a target ratio of
RNA to ribozyme in the cleavage reaction of 1:4. The reac-
tion was stopped by adding 10id of polyacrylamide loading
buffer (8 M urea, 0.03% BB, 0.03% XC) to the solution. A
vohlume of 20#l wash then loaded onto a 10% polyacryl-
amide-7 M urea gel. Electrophoresis was carried out at 40 W
for approximately 4h. The bands were visualised by auto-
radiography.
Plasid construction
The ribozyme sequence was introduced into the eukaryotic
expression vector pHPAPr-I neo (Gunning et al., 1987), which contains a P-actin promoter sequence and a gene for
neomycin selection. The plasmid containing the ribozyme
sequence pHPAPr-I neo/mdr-Rb was constructed according
to the protocol described by Kashani-Sabet et al. (1992).
Cell lines
The primary culture of human pancreatic carcinoma cell line
EPP85-181P was previously established as described else-
where (Dietel et al., 1988, 1990). The cells were grown in
Leibowitz 15 medium supplemented with 10% fetal calf
d
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serum (FCS) (Dietel et al., 1990). By growing the parental
cells EPP85-181P in increased concentrations of daunorubi-
cin, a resistant cell line was selected (EPP85-181RDB). The
MDR phenotype was established by demonstrating cross-re-
sistance against doxorubicin, vincristine and daunorubicin
(data not shown). The MDR phenotype was mediated by
overexpression-of the mdrl gene, which was demonstrated by
reverse transcription (RT)-PCR (data not shown), by North-
ern blot analysis (see below) and by immunocytochemistry
against the P-glycoprotein using the monoclonal antibody
C-219) (Centocor (Dietel, 1991).
Northern blot analisis
Total RNA was extracted using the acid guanidinium
thiocyanate method (Chomczynski & Sacchi, 1987). Ten
micrograms of total cellular RNA was electrophoresed on
0.8% agarose gels containing 2.2 M formaldehyde. The RNA
was then capillary transferred to a nylon membrane (Zeta
Probe. Bio-Rad). A probe was generated by amplifying a
785 bp DNA fragment of the plasmid PI-4/HaeIII (primer
sequences: GAAGAATTCAGCTrAGTACCAAAGAGGCr,
GAAGGATCCCCTGCAAACTCTGAGCAT). This DNA
fragment (30 ng) was labelled by using the random primer
DNA-labelling system (Amersham). Hybridisation was per-
formed as previously described (Kashani-Sabet et al., 1992).
The 785 bp fragment was hybridised at 65°C overnight. The
filters were washed twice with 6 x SSC and 0.1% SDS at
37°C for 30 min. and were exposed by autoradiography for I
day. A 1.1 kb cDNA probe against the phosphoglycerate
kinase mRNA served as an internal control for the Northern
blot analysis.
Transfection
The transfection of the resistant cell line EPP85-181RDB
with the plasmid pHPAPr-l neo/mdr-Rb was carried out by
electroporation as described by Kashani-Sabet et al. (1992),
using an IBI Gene Zapper. Transfection with the plasmid
pHPAPr-l neo without the ribozyme sequence served as a
negative control. This excludes the possibility that reversion
of the mdr phenotype might be a consequence of plasmid
incorporation. Cell clones were selected by adding 500yg
ml-' G418 (geneticin sulphate) for 4 weeks to the cell culture
medium. The transfected cell clones were charactenrsed as
descnrbed above.
Monolayer proliferation assay to assess ICs
As a functional assay to determine daunorubicin resistance,
the cell lines and the selected clones were subjected to a
monolayer proliferation assay as described by Dietel et al.
(1990). The IC50 is the concentration that inhibits cell growth
by 50%. The factors of resistance were calculated by dividing
the IC^ of the resistant cell line by the IC, of the sensitive
cells or the clones containing the ribozyme.
RT-PCR assay followed by Southern blot analisis
To confirm the expression of the ribozyme and the vector
pHPAPr-l neo, whole cells (1,000 cells ml-') were lysed by
boiling for 8mn in one part 20% Chelex (Bio-Rad) and
three parts water. A total reaction volume of 50;Ll, contain-
ing 3.75 units of reverse transcriptase (Promega), I x PCR
buffer (100 mM Tris, pH 8.0, 500 mM potassium chloride,
15 mM magnesium chloride), 2.5 mM dNTPs and 20 pmol of
the two primers rib VI (AGCACAGAGCCTCGCCTTT)
and rib V2 (GTCTGGATCCCTCGAAGC), and 5IlI of the
lysed cells were incubated for 30 min at 37C. The samples
were then denaturated by heating at 94°C for 3 min. The
PCR was initiated by adding 5 units of Taq DNA
polymerase (Promega) to the 50;lI reaction volume. The
amplification products were electrophoresed in 1.9% agarose
gel containing I x TAE. The products were capillary trans-
ferred onto a nylon membrane (Zetaprobe, Bio-Rad) and
hybridised as described above to a 5'-'2P-labelled oligo-
nucleotide rib probe (CGTCCTCACGGACTCATCAG),
which was situated within the PCR product and is comple-
mentary to the core sequence of the ribozyme. As positive
control for successful hybridisation we used the plasmid
pHPAPr-I neo 'mdr-Rb, primer rib V2 (sequence given
above) and primer vecl (GCCTTT-TATGGTAATAACGC)
to amplify a 220 bp DNA fragment containing the sequence
of the ribozyme.
To analyse the expression of the plasmid pHPAPr-l neo.
the primers rib VI (see above) and rib V2 (see abcve) were
used for RT-PCR. The oligonucleotide Vp (ATCAGT-
CGACCTGCAGCCC) served as a probe for Southern hy-
bridisation (data not shown).
Results
In vitro analysis
Cleavage of the target RNA by the ribozyme is shown in
Figure lb. After 60min, almost all the 240 base target RNA
substrate was cleaved into a 137 base product and a 103 base
product, while the 43 base ribozyme remained unaffected.
Optimal conditions for cleavage of the substrate by the
ribozyme were approximately pH 8.0, 12 mM magnesium
chloride and 52°C (data not shown).
Ribozyme expression in transformed cell clones
After transfection of the pancreatic carcinoma cell line
EPP85-181RDB with the plasmid pHPAPr-l neo/mdr-Rb,
ten cell clones survived the selection by G418. Two of these
clones showed stable expression of the ribozyme (Figure Ic,
lanes A and B). These were designated EPP85-18RDB-Rbl
and EPP85-181RDB-Rb2. In contrast, no ribozyme expres-
sion was detected in either the untransfected cell line EPP85-
181P, clone EPP85-181RDB or clone EPP85-181RDB/Vec.
This last clone was obtained by transfecting the resistant cell
line (EPP85-181RDB) with the plasmid pHPAPr-l neo only.
Figure Id displays a section of the expression vector
pHPAPr-l neo/mdr-Rb and the specific oligonucleotides re-
sponsible for detection of the expressed ribozyme. Using the
two primers rib Vl and rib V2 a 120 base spliced ribozyme
product was amplified. If only the expression vector
pHPAPr-l neo/mdr-Rb served as a template for PCR, a
950 bp DNA molecule was amplified.
Expression ofmdrl mRNA
Northern blot analysis (Figure 2) showed that in the clones
containing the ribozyme (lanes 2 and 3), and in the sensitive
cell line EPP85-181P (lane 4) grown in 0.0125Sggm[1l'
daunorubicin, the level of mdrl mRNA was reduced to the
point at which it could no longer be detected. In contrast, the
cell clone containing the plasmid pHiAPr-l neo showed a
strong signal (lane 1). The resistant cell line EPP85-181RDB,
when grown in different concentrations of daunorubicin
(lanes 5, 6 and 7), showed expression of the mdrl mRNA
that correlated with the different daunorubicin concentra-
tions. When grown without daunorubicin, the resistant cell
line showed no signal (lane 5), the cell line grown in
0.025nggmnl' showed a weaker signal (lane 6) and a con-
siderably stronger signal was observed with 2.5jg m1'
daunorubicin (lane 7). When we cultivated the cell clones
EPP85-181RDB-Rbl/2 in increasing concentrations of
daunorubicin, the cells were only able to tolerate concentra-
tions up to 0.0125 igml-' daunorubicin.
Immunocytochemicalanaljsis
This is shown in Figure 3. Neither the parent cell line EPP85-
181P (Figure 3c), which is sensitive to daunorubicin, nor the
clones containing the ribozyme exhibited P-glycoprotein
immunoreactivity using the monoclonal antibody C-219
(Figure 3b). P-glycoprotein could be detected in the resistant242 P.S. HOLM et al.
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Fugwe 2 Northern blot analysis of mdrl mRNA using a 785 bp
probe. The autoradiograph demonstrates no detectable signal
with Il0ig of total cellujlar RNA of EPP85-181lRDB-Rbl1/2 (lanes
2 and 3) and EPP85-181P (lane 4) grown in 0.0125jgm]l'
daunorubicin The resistant cell lin (EPP85-181RDB) and the
cell hine containing the vector (EPP85-181RDB/Vec) when grown
in 2.5 zg m1-' daunorubicin show a clear hybridisation signal
(l,anes 1 and 7). The resistant cell line EPP85-181RDB shows a
weaker signal when grown in 0.025 ug ml' daunorubicin (lane
6), and almost no signal when grown in the absence of
daunorubicin (lane 5).
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Fa,we 3 Immunocytochemistry of P-glycoprotein in the human
pancreatic carcinoma cell line EPP85-181RDB a, EPP85-181P c,
EPP85-181RDB/Vec i, EPP85-181RDB-Rbl b, with labelling of
the cell membrane in a and d. The monoclonal antibody C-219
was used for the detection (a, b and d, 400 x; c, 200 x ). The
cells clones in a and d were grown in 2.5 zg ml-' daunorubicin
and those in b and c in 0.0125zgml-' daunorubicin.
cell line EPP85-181RDB and in the control clone (EPP85-
181RDB/Vec), which contained the vector alone (Figure 3a
and d).
Monolayer proliferation assa)
The results of the monolayer proliferation assay are shown in
Figure 4. The resistant cell line EPP85-181RDB, which has
an IC5o of 12iLg ml-', is approximately 1,600-fold more resis-
tant to daunorubicin than the parental EPP85-181P cell line,
which has an IC50 of about 0.0075 igml-'. In both clones
(EPP85-181RDB-Rbl/2) that contain the ribozyme the resis-
tance was reduced dramatically. IC5( values for the two
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Fagwe 4 Determination of the daunorubicin-induced IC50 for
parent and resistant cell lines (0, EPP85-181P; 0, EPP85-
181RDB), the two cell lnes containing the ribozyme (-, EPP85-
181RDB-Rbl; 0, EPP85-l8lRDB-Rb2), and the cell line contain-
ing only the expression vector (A, EPP85-181RDB/Vec). Data
points represent cell counts of cultures.
clones containing the ribozyme were decreased from about
12 Lg ml-' daunorubicin in the resistant cell line to
0.03 tLg ml-' and 0.04gg ml-' respectively. The expression of
the ribozyme reduced the resistance from 1,600-fold to about
5.3-fold. This is a reduction of the resistance to daunorubicin
of about 300-fold. The clone which contained the expression
vector (EPP85-181RDB/Vec) continued to be as resistant to
daunorubicin as the original resistant cell line EPP85-
181RDB. The reversal of resistance achieved with doxo-
rubicin and vincristine is in the same range as that achieved
with daunorubicin.
A hammerhead ribozyme was designed to cleave the 3'-end
of the GUC triplet in exon 21 of the mdrl mRNA in
P-Gp-positive human pancreatic carcinoma cells exhibiting
the MDR phenotype. The target site was chosen between the
two ATP binding sites, which may be important for the
function of the P-Gp as an ATP-dependent pump (Cornwell
et al., 1987). Prior to testing the ribozyme in tissue culture,
we investigated its ability to cleave the target sequence of the
mdrl mRNA in a cell-free system. Although in this test a
relatively high ratio of ribozyme to substrate (4:1) was
employed, the catalytic activity of the ribozyme is sufficient
to cleave at smaller ratios (up to 1:4, data not shown). A
mammalian expression vector containing the 43 bp DNA
sequence that encodes the mdrl ribozyme was transfected
into the pancreatic carcinoma cell line EPP85-181RDB. Two
cell clones that expressed the ribozyme (EPP85-181RDB-
Rbl/2) were isolated. The amount of mdrl mRNA was
reduced to such an extent that it was no longer detectable; at
the same time, no P-Gp formation was observed. The overex-
pression of mdrl mRNA is inhibited by the ribozyme and
therefore only a very small amount of mdrl mRNA is prob-
ably still present and cannot be detected by Northern blot
analysis. In contrast, using the RT-PCR technique, the
ribozyme-expressing cell clones grown in 0.0125p1gml-
daunorubicin-supplemented medium gave a clear MDR-
specific signal (not shown). The expression of the ribozyme
resulted in a 300-fold reduction in resistance. Whether the
reduction of resistance is the result of a high level of
ribozyme expression and/or a high ribozyme cleavage
efficiency (or antisense function) in the transformed cell
clones remains to be studied.
We were able to determine that upon increasing the con-
centration of daunorubicin in the medium, the expression of
the mdrl mRNA (Figure 2), the formation of P-glycoprotein
and the cells' resistance was increased (data not shown). The
extent of the reduction in resistance in our cell line EPP85-
181RDB-Rbl/2 suggests that P-glycoprotein is in this case
the major mechanism of resistance. The fact that it was not
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possible to reinduce resistance by exposing the two clones
(EPP85-181RDB-Rbl/2) to daunorubicin confirms that this
ribozyme is responsible for reversing MDR; in contrast, it
was possible to reinduce resistance to daunorubicin in the cell
line EPP85-181RDB, which was grown for a long period
without this cytostatic drug. The cell clone expressing the
vector only had no effect of mdrl gene expression and dis-
played the same degree of drug resistance as EPP85-181RDB
cells. The slight remaining cytotoxic difference between the
parent cells EPP85-181P and clones containing the ribozyme
may be due to either other drug resistance mechanisms or
residual amounts of P-glycoprotein. This MDR ribozyme
also works in other cell lines, such as ovarian carcinoma
A2780 cells resistant to dactinomycin and small-cell lung
carcinoma H69 cells resistant to VP-16 (K.J. Scanlon, unpub-
lished data).
Ribozymes have been proposed as anti-HIV agents (Sarver
et al., 1990) and as tools to help study gene expression as
well as to confer malignant phenotype (Scanlon et al., 1991;
Kashani-Sabet et al., 1992). Our experiments show that our
ribozyme can be targeted to inhibit the expression of the
mdrl gene, and may represent a potential help in an addi-
tional strategy of cancer treatment. In the last few years it
has been demonstrated that modified bases of the ribozymes
make them resistant to nuclease degradation and very stable
in serum (Pieken et al., 1991; Paolella et al., 1992). We intend
to investigate the possibility of applying a modified ribozyme
directly to the cell culture, thus increasing its usefulness for
therapeutic applications.
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Abmeviaiom MDR, multidrug resistance; P-Gp, P-glycoprotein;
PCR, polymerase chain reaction; RT, reverse transcription; cDNA.
complementary DNA, SDS, sodium dodecyl sulphate; G418,
geneticin sulphate; FCS, fetal calf serum; IC50, drug concentration
inhibiting cell growth to 50% of control; Rb, ribozyme; S, mdrl
mRNA; PGK, phosphoglycerate kinase; bp, base pair; BB, brom-
phenol blue; XC, xylencyanol; kb, kilobase.
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